Regression of Cardiac Rhabdomyomas in a Neonate after Everolimus Treatment


Bornaun H., Oztarhan K., Erener-Ercan T., Dedeoglu R., Tugcu D., Aydogmus C., ...More

CASE REPORTS IN PEDIATRICS, 2016 (ESCI) identifier identifier

Abstract

Cardiac rhabdomyoma often shows spontaneous regression and usually requires only close follow-up. However, patients with symptomatic inoperable rhabdomyomas may be candidates for everolimus treatment. Our patient had multiple inoperable cardiac rhabdomyomas causing serious left ventricle outflow-tract obstruction that showed a dramatic reduction in the size after everolimus therapy, a mammalian target of rapamycin (mTOR) inhibitor. After discontinuation of therapy, an increase in the diameter of masses occurred and everolimus was restarted. After 6 months of treatment, rhabdomyomas decreased in size and therapy was stopped. In conclusion, everolimus could be a possible novel therapy for neonates with clinically significant rhabdomyomas.